Efficacy of aclacinomycin plus intermediate dose of cytarabine for patients with refractory and relapsed acute myeloid leukemia.

Objective:To observe the efficacy and safety of aclacinomycin (Acla) plus intermedium-dose cytarabine (ID Ara-C) (AA regimen) on patients with refractory and relapsed acute myeloid leukemia (AML). Methods:Twenty-six patients with refractory and relapsed AML received rescue therapy with AA regimen. The clinical outcome and adverse reaction were evaluated. Results:After 2 cycyles of rescue therapy with AA regimen, 12 cases achieved complete response (CR), 7 cases achieved partial response (PR), and 7 patients had no response. One was dead because of severe infection. Conclusion:AA regimen is effective in the treatment of refractory and relapsed AML. Most patients are well tolerated.